Biomarkers of Lung Disorders
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (25 March 2025) | Viewed by 2165
Special Issue Editors
Interests: pulmonary involvement in collagen-vascular diseases (especially interstitial lung disease and pulmonary hypertension)
Special Issues, Collections and Topics in MDPI journals
Interests: medical imaging in respiratory diseases
Interests: COPD; asthma; interstitial lung fibrosis; pneumonia; pulmonary hypertension
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Biomarkers are represented by any genetic, molecular, histological, biochemical, immunological, or imagistic measurable indicators, which can help early diagnosis, even from the subclinical stages of a disease, can stratifying the evolution risk, and assessing the therapeutic response. They must have high specificity, good discriminative capacity and be easy to determine. Chronic respiratory diseases are an important public health problem, due to their increased prevalence, imposing increased costs for care. That is why their early diagnosis and appropriate treatment is important. Biomarkers can fulfill these requirements. Since chronic respiratory diseases are very diverse, it is necessary to identify specific biomarkers for each type of pathology. Some of these biomarkers are: histidine-rich glycoprotein (HRG), α1-acid glycoprotein (AGP1), α1-antitrypsin (α1AT) and fibronectin (COPD), blood and sputum eosinophils, IgE, vitamin D, serum CD26 and CD14, FeNO (asthma), MUC5B polymorphisms, KL6, SP-A, SP-D, CC16, YKL40, MMP1, MMP7, LOXL2, CCL18, IL-6, osteopontin (interstitial lung diseases), NT-proBNP, uric acid, endothelin 1, angiopoietin 2, interleukins (IL-6, IL-8, IL-10) (pulmonary hypertension), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene 1 (ROS1), B-Raf proto-oncogene (BRAF), neurotrophic tyrosine receptor kinase (NTRK) and programmed cell death-1 (PD-1) and/or programmed cell death ligand-1 (PD-L1) (lung cancer). These biomarkers, but also others that have not been listed, together with imaging methods (thoracic ultrasonography and high-resolution computed tomography), contribute to the early diagnosis and the appropriate therapeutic strategy in lung pathology.
Dr. Alexandru Caraba
Dr. Diana Manolescu
Dr. Ovidiu Fira-Mladinescu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- thoracic ultrasonography
- pulmonary high resolution computed tomography
- COPD
- asthma
- pneumonia
- pulmonary hypertension
- interstitial lung diseases
- lung cancer
- collagen vascular diseases
- cardiac failure
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
